Skip to content

PAR-25-379 Native Health R01 Eligibility Guide

Updated 5 official sources

Quick Answer: PAR-25-379 eligibility in 2026 turns on 6 checks: Native health focus, community partnership, intervention logic, clinical-trial classification, R01 readiness, and participating-institute fit.

Full answer and how we checked it

Compare PAR-25-378 R34 when planning or feasibility work is still needed.

Who this is for: Tribal health researchers, Native-led research teams, Urban Indian health partners, Native Hawaiian health partners, intervention scientists, and sponsored-research offices deciding whether an NIH R01 is the right route.

Data note: This guide uses NIH PAR-25-379 (opens in a new tab), companion NIH PAR-25-378 R34 (opens in a new tab), NIH clinical trials policy (opens in a new tab), NOT-AR-25-017 (opens in a new tab), Grants.gov listing 358375 (opens in a new tab), all checked on October 10, 2026, with due dates rechecked October 24, 2026.

In this guide

PAR-25-379 is not a generic health disparities R01. According to NIH PAR-25-379 (opens in a new tab), the NOFO supports research on interventions and related work to improve health in Native populations.

In NIH community-engaged applications, the central problem is often not weak science. It is weak partnership logic. For this route, the application has to show community fit, cultural relevance, intervention readiness, and institute fit without treating the community as a recruitment channel.

Use this guide with the live NIH Native Health Intervention R01 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, grants for substance abuse programs, what is a NOFO, and the Grantsights grant database.

October 2026 Source Check

As of October 24, 2026, PAR-25-379 is still the NIH R01 clinical-trial-optional route for Intervention Research to Improve Native American Health, but its last listed due date, October 21, 2026, has passed. NIH names no successor NOFO yet, says AIDS dates are not applicable after NIH removed AIDS dates from this NOFO, and lists January 8, 2027 as the expiration date. NIH also added NIAMS participation through NOT-AR-25-017, effective for the October 21, 2025 due date and subsequent due dates, so musculoskeletal, skin, and arthritis-related Native health projects should recheck institute fit before submission.

The March 31, 2025 source update matters for applicants because NIH tells teams to reread the full opportunity and adjust applications. The strongest public screen is now: prove Native community priority, governance, data rights, community review, intervention readiness, clinical-trial classification, R01 versus R34 fit, and participating-institute mission match before drafting aims.

Current source ownerWhat the applicant should do
NIH PAR-25-379Watch for a reissue (its last due date, October 21, 2026, has passed), then confirm trial-optional status and participating institute list
NIH PAR-25-378Use the R34 when governance, feasibility, protocol, recruitment, or outcome-measure work is not ready for R01 scale
NIH noticesCheck AIDS-date removal and NOT-AR-25-017 NIAMS participation before copying an old calendar
Grants.gov listing 358375Use as a federal record cross-check, not the only source

Get grant deadline alerts by email

About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.

No spam. Unsubscribe anytime.

6 PAR-25-379 Eligibility Stop Checks

6 stop checks decide whether the R01 fits. The project should center Native health, community partnership, intervention logic, clinical-trial classification, and participating-institute fit.

Stop checkStrong R01 signalRed flag
Population fitNative community focus is explicitPopulation is incidental
Community roleCommunity partners shape design and conductPartners only help recruit
Intervention logicDevelopment, testing, adaptation, or implementation path is clearBroad needs assessment only
Mechanism scaleR01-ready design and teamPlanning work belongs in R34
Trial statusClinical-trial status is explicitForms and protocol are unclear
Institute fitParticipating NIH institute mission match is clearNo institute fit

Don't use this route as a label for any project with Native participants. The project should be built with community knowledge, resources, and priorities visible in the design.

5 Funding, Timing, and Mechanism Rules

5 public rules should appear before the specific aims page. According to NIH, PAR-25-379 is an R01 clinical trial optional NOFO. Its last due date was October 21, 2026, no due dates remain, and the NOFO expires January 8, 2027.

RuleSource-backed read
Funding numberPAR-25-379
MechanismR01 research project grant
Clinical trial statusOptional
Companion planning routePAR-25-378 R34
Next due dateNone remaining; the last one was October 21, 2026
Expiration dateJanuary 8, 2027

According to NIH, application budgets are not limited but must reflect project needs, and the total project period may not exceed 5 years.

5 R01 Versus R34 Route Choices

5 route choices matter before writing. The R01 is for a research project ready to proceed. The R34 is for planning, development, or feasibility work before a larger trial or project.

RouteBetter first read when...Why
PAR-25-379 R01Intervention or related research is ready for full studyR01 scale fits
PAR-25-378 R34Trial or project needs planning and feasibilityPlanning route fits
Parent R01Native health is relevant but IRINAH scope is not rightBroader route may fit
Institute-specific NOFODisease area has a better targeted pathReview fit may improve
Tribal or HRSA routeProgram service delivery is the main needNIH research route may not fit

The honest answer is that the R34 may be the better first step when trust, governance, protocol, recruitment, or feasibility work still needs to be built.

What NIH Doesn't Tell You

4 hidden readiness questions decide whether this belongs under PAR-25-379. NIH gives the public rules, but it does not decide whether the partnership is real enough for review.

First, NIH does not make community engagement real because a letter exists. Governance, data rights, decision-making, compensation, and dissemination should be visible.

Second, NIH does not make all Native health research intervention research. Etiologic work can fit when it directly informs intervention development, but the path has to be stated.

Third, NIH does not remove clinical-trial complexity. If the study assigns an intervention to study health outcomes, the team should handle trial design, safety, data monitoring, and forms early.

Fourth, NIH does not guarantee institute fit. According to NIH, applications that do not align with a participating institute mission may be considered non-responsive.

One research team working with a Tribal health partner should be able to name the decision body, data-use terms, community review process, and return-of-results plan before writing aims. If those pieces are not real, skip the R01 for now and choose a better route, often PAR-25-378 R34 or a non-NIH service-funding path.

7 Evidence Assets That Make This R01 Stronger

7 evidence assets help a Native health R01 read as review-ready. The strongest application proves partnership, research fit, and next-step value.

First, define the Native population and community context. According to NIH, the NOFO includes American Indian, Alaska Native, Urban Indian, state-recognized Tribal, and Native Hawaiian communities as described in the announcement.

Second, show community governance. A tribal partner with a community advisory board, data-use agreement, cultural review process, and PI partnership has a stronger foundation than a university-only study.

Third, explain the intervention path. The project may develop, adapt, test, or study adoption of an intervention, but it should not read like a service program without research questions.

Fourth, connect cultural fit to design, not just language. Recruitment, measures, consent, intervention content, staffing, data return, and dissemination can all require community-specific decisions.

Fifth, handle sustainability and scale carefully. According to NIH, research may address adoption, integration, scale-up, and sustainability of effective interventions when evidence already supports that step.

Sixth, make clinical-trial status explicit. Clinical trial optional does not mean forms are optional.

Seventh, name the participating institute fit. The application should explain the disease area, institute mission, and program staff logic before submission.

21-Day Native Health R01 Routing Plan

21 days is enough to decide whether the team should draft. Days 1 through 3 should confirm source status, deadline, clinical-trial status, and participating institute fit.

Days 4 through 7 should test community readiness: governance, letters, data agreements, compensation, consent, dissemination, and community review.

Days 8 through 12 should compare R01 and R34. If protocol, recruitment, or intervention adaptation is still uncertain, the R34 may be cleaner.

Days 13 through 16 should write the intervention logic: problem, community knowledge, mechanism, outcomes, measures, trial status, and analysis.

Days 17 through 21 should run submission checks, including budget, human subjects, Tribal approvals if applicable, and program staff contact.

6 Reviewer-Risk Signals to Fix

6 risk signals should be fixed before submission. First, the application should not treat Native communities only as a study population.

Second, the intervention should not be culturally adapted in name only.

Third, the clinical-trial status should be explicit.

Fourth, institute fit should be named early.

Fifth, data governance should be clear, especially for community-level or Tribal data.

Sixth, the project should show how findings will return to the communities involved.

7 Source-Backed Signals From PAR-25-379

7 signals from NIH should shape this page and the applicant's routing memo. The first is that PAR-25-379 is an R01, so the research plan should be ready for full project review rather than only planning.

The second is clinical-trial optional status. A trial may fit, but the trial classification, human-subjects record, data monitoring plan, and protocol logic need to be settled early. They can't be patched at the end.

The third is community priority. NIH asks applicants to show that the research question is relevant to and prioritized by Native community partners. A letter alone won't prove that.

The fourth signal is cultural and community fit. The design should show how community knowledge, strengths, and local context affect measures, staffing, recruitment, intervention content, data rights, and dissemination.

The fifth signal is the R34 comparison. PAR-25-378 exists for teams that still need planning, feasibility, or protocol work. If governance or intervention design is still unsettled, the R34 may be cleaner.

The sixth signal is participating-institute fit. The disease area and mission match should be named before submission because non-responsive applications can lose before review.

The seventh signal is sustainability. NIH asks for work that can matter in the test communities and, when appropriate, support wider use. The application should be honest about what can scale and what should remain community-specific.

4 Signals To Check Before You Draft

4 signals help you decide whether to draft. Signal 1 is partnership readiness: community partners should shape design, conduct, data rights, and dissemination.

Signal 2 is route fit: compare PAR-25-379 R01 with PAR-25-378 R34 when governance, protocol, recruitment, or feasibility work is not settled.

Signal 3 is trial fit: clinical trial optional status still requires correct classification, forms, protocol logic, and monitoring.

Signal 4 is institute fit: the application needs a clear participating-institute match before submission.

5 Applicant Types and Best Next Move

5 applicant types commonly ask about PAR-25-379, and each should leave with a different next step.

Applicant typeBest next moveWhy
Native-led research teamBuild R01 fit memoRoute may fit
University with community partnerConfirm governance and data rightsPartnership quality matters
Trial-planning teamCompare PAR-25-378 R34Planning route may fit
Service programCompare HRSA or Tribal fundingNIH requires research aims
Sponsored-project officeCheck trial status and institute fitTechnical issues can block

The best answer is: use PAR-25-379 when the project is community-grounded, Native health centered, research-ready, correctly classified for trial status, and aligned with a participating NIH institute.

Sources

4 sources anchor this guide: the NIH R01 NOFO, the companion NIH R34 planning route, the federal listing, and the Grantsights public database record.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does PAR-25-379 fund?

NIH says the R01 supports intervention and related research to improve health in Native populations.

Are clinical trials allowed?

Yes. PAR-25-379 is clinical trial optional.

What is the companion planning route?

NIH lists PAR-25-378 as the R34 clinical trial planning route.

What populations are included?

NIH defines Native Americans broadly for this NOFO, including American Indian, Alaska Native, Urban Indian, state-recognized Tribal, and Native Hawaiian communities as described in the NOFO.

Who should skip this route?

Skip it if the project lacks community partnership, cultural fit, intervention logic, or participating-institute fit.

Last updated October 24, 2026. Corrected October 24, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.